Bristol Myers Squibb (NYSE: BMY) is one of the more interesting large-cap setups in U.S. healthcare heading into the final quarter of 2026. The stock trades at $63.70, around 9.7x consensus forward earnings, with a dividend yield near 4.0%. Meanwhile, the company has just delivered a quarter that beat consensus by a wide margin. Second-quarter 2026 revenue rose 6% to $12.97 billion. The Growth Portfolio expanded 15% to $7.56 billion, and management raised full-year revenue guidance by about $2.75 billion at the midpoint, to about $49.0–50.0 billion, and non-GAAP EPS guidance to $6.75–7.00. The market still prices BMY as a melting ice cube, because Eliquis and Opdivo, together about half of 2025 revenue, face U.S. loss of exclusivity in 2028. The next six to twelve months of Bristol Myers Squibb pipeline readouts will decide which story wins.
We think the risk/reward is favorable, for three reasons.
1. The base business is outperforming its own guidance. In February, management guided 2026 revenue to $46.0–47.5 billion and expected Eliquis to grow 10–15%. By July, Eliquis guidance had doubled to 20–25% growth. Worldwide Eliquis revenue reached $4.48 billion in Q2, up 22%, as the Medicare negotiated price that took effect in January 2026 widened patient access. Reblozyl (+29%), Breyanzi (+41%) and Camzyos (+60%) all compounded strongly. This is not a company in decline today.
2. The valuation already discounts a painful cliff. At 9.7x forward EPS and roughly 3.3x EV/Sales, BMY trades at the lowest forward P/E in the five-company large-cap pharma peer set we compare below. Consensus 2027 EPS of $6.56 already sits below 2026 guidance, so the Street is modeling erosion. What the price does not reflect is a scenario where even one or two late-stage assets land.
3. Binary catalysts are clustered in a short window. The LIBREXIA-STROKE Phase 3 study of milvexian (partnered with Johnson & Johnson) is still expected to read out by year-end 2026. The admilparant Phase 3 in idiopathic pulmonary fibrosis (IPF) is also expected by year-end, and an interim look at ADEPT-1 (Cobenfy in Alzheimer’s disease psychosis) could come in late 2026. On top of that, iberdomide (brand name Zenbexus) won FDA accelerated approval in August, and mezigdomide has a PDUFA date of May 13, 2027.
This article covers BMY’s business model and segment mix, a deep industry analysis of the pharma patent cliff and the growth pools BMY is targeting, its economic moat, five years of financials, a step-by-step valuation with bull/base/bear targets, the key risks, and a concrete exit plan.
—
1. Company Overview: From Legacy Blockbusters to a “Growth Portfolio” Company
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey. It makes money the way most large pharma companies do: it discovers, acquires, develops and sells patent-protected prescription medicines at high gross margins, then reinvests part of those cash flows into R&D and business development to replace products before their patents expire. The company does not sell generics or consumer health products, so almost all of its revenue comes from branded, specialty and primary-care medicines.
Today’s BMY was built largely through acquisitions: Celgene in 2019 (hematology and cell therapy), MyoKardia in 2020 (Camzyos for obstructive hypertrophic cardiomyopathy) and Karuna Therapeutics in 2024 (Cobenfy for schizophrenia). Management now reports revenue in two buckets:
– Growth Portfolio: newer or still-growing medicines, including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Sotyktu, Krazati, Cobenfy and royalties.
– Legacy Portfolio: Eliquis (co-commercialized with Pfizer) plus older drugs facing generic competition, such as Revlimid, Pomalyst, Sprycel and Abraxane.
Revenue breakdown — Q2 2026 (worldwide, $ millions)
Product Q2 2026 Revenue YoY Change Portfolio Therapeutic Area Eliquis 4,481 +22% Legacy Cardiovascular Opdivo 2,485 -3% Growth Oncology (IO) Orencia 1,034 +7% Growth Immunology Yervoy 769 +6% Growth Oncology (IO) Reblozyl 735 +29% Growth Hematology Other Growth Products 653 +17% Growth Various / royalties Breyanzi 484 +41% Growth Cell therapy Revlimid 425 -49% Legacy Hematology Camzyos 416 +60% Growth Cardiology Opdualag 349 +23% Growth Oncology (IO) Opdivo Qvantig 261 >200% Growth Oncology (subcutaneous IO) Pomalyst/Imnovid 204 -71% Legacy Hematology Zeposia 169 +12% Growth Immunology Sotyktu 87 +23% Growth Immunology Cobenfy 63 +81% Growth Neuroscience Krazati 55 +14% Growth Oncology Total 12,973 +6%
Source: BMS Q2 2026 earnings release (8-K, July 30, 2026). Totals may not sum due to rounding and other revenue.
Two features of this mix matter for investors. First, the Growth Portfolio is now the majority of the business. It made up 54.8% of 2025 revenue ($26.4 billion of $48.2 billion) and 58.3% of Q2 2026 revenue. Second, concentration is still high. Eliquis alone produced 34.5% of Q2 revenue, and Eliquis plus Opdivo accounted for about $24.5 billion, or roughly 51%, of 2025 revenue. Both face U.S. generic or biosimilar competition around 2028. Under patent settlements, generic apixaban (Eliquis) can enter the U.S. market on April 1, 2028.
Geographically, U.S. revenue was $9.0 billion in Q2 (69% of the total) and international revenue was $4.0 billion. The U.S. skew means American pricing policy, including Medicare negotiation under the Inflation Reduction Act (IRA), matters more for BMY than for peers with bigger ex-U.S. footprints.
Market position. In immuno-oncology, Opdivo is a major PD-1 inhibitor competing directly with Merck’s Keytruda. BMY’s differentiation now comes from combinations (Opdualag, the PD-1 + LAG-3 fixed-dose combination) and delivery (Opdivo Qvantig, a subcutaneous formulation). In hematology, the Celgene franchise gives BMY a deep multiple myeloma and anemia presence through Revlimid, Pomalyst, Reblozyl, the CAR-T therapies Breyanzi and Abecma, and now the CELMoD class (iberdomide, mezigdomide). In cardiovascular care, Eliquis is a guideline-endorsed standard of care for stroke prevention in atrial fibrillation (AF), and Camzyos is a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Ownership and governance. BMY has about 2.04 billion shares outstanding and is widely held by large institutional index and active managers, as is typical for a mega-cap S&P 500 constituent; insider ownership is small. Christopher Boerner, Ph.D., serves as board chair and chief executive officer. Capital allocation priorities are stated plainly: R&D focus on “high-impact, transformational medicines,” operational execution in the Growth Portfolio, and “disciplined capital allocation” supporting the dividend, which was raised in December 2025 to $0.63 per quarter (first paid in February 2026), the 17th consecutive annual increase.
—
2. Industry Analysis: The Pharma Patent Cliff Meets a New Innovation Cycle
2-1. Market Size & Growth Trajectory
The global prescription medicine market is large, growing and resilient to recessions. According to the IQVIA Institute, global spending on medicines is expected to reach about $2.3 trillion by 2028, and IQVIA’s more recent outlook calls for roughly 5–8% compound annual growth through 2030, to around $2.6 trillion. Oncology is a major growth category: IQVIA projects oncology spending will exceed $440 billion by 2028, with around 100 new cancer treatments expected over five years.
Where does the industry sit in its cycle? We would describe large-cap pharma as mature at the aggregate level but in an acceleration phase within specific therapeutic pools. Aggregate revenue growth for big pharma is mid-single digit. Underneath that average, three pools are growing much faster: (1) next-generation oncology modalities such as antibody-drug conjugates (ADCs), bispecific antibodies and cell therapies; (2) cardiometabolic disease, including obesity, HCM and next-generation anticoagulation; and (3) neuroscience and immunology, where new mechanisms are opening markets that were stuck on decades-old drugs.
The defining feature of this cycle is the 2026–2030 loss-of-exclusivity (LOE) wave. Industry estimates put a very large amount of branded revenue, commonly cited in the $200–300 billion range (est.), at risk from generic and biosimilar entry through the end of the decade. Keytruda, Eliquis, Opdivo, Darzalex IV and several other top-selling drugs all lose key U.S. protection in roughly the same window. For BMY this is not an abstract industry trend. It is the central fact of the investment case.
2-2. Structural Growth Drivers
Driver 1: Replacement demand creates a seller’s market for late-stage assets. Because so much revenue rolls off patent at once, large pharma companies are competing hard to buy or license late-stage and even early-stage assets. That raises acquisition prices, which is a headwind for buyers like BMY. It is also a tailwind for BMY’s own pipeline value, because a de-risked Phase 3 asset commands a premium in this market. BMY has been an active dealmaker. In May 2026 it signed a collaboration with China’s Hengrui Pharma covering 13 early-stage programs in oncology, hematology and immunology, a deal reported at up to $15.2 billion in total potential value. China has become a critical source of external innovation: BMY’s partnership with SystImmune on iza-bren (izalontamab brengitecan), a bispecific ADC, produced positive Phase 3 interim results in China in June 2026 in both triple-negative breast cancer and esophageal squamous cell carcinoma. In the short term these deals add expense. Over the long term they are the main way large pharma refills its pipeline at acceptable cost.
Driver 2: Anticoagulation is shifting toward safer mechanisms. Atrial fibrillation affects roughly 10 million people in the U.S., and a large share of eligible patients are either untreated or discontinue anticoagulants because of bleeding fears. Factor XI/XIa inhibition is a closely watched new cardiovascular mechanism. The hypothesis is that blocking Factor XIa prevents pathological clots while largely sparing the clotting needed to stop bleeding. If that hypothesis holds, the class could expand the treated population rather than just take share from Eliquis and Xarelto. The evidence so far is mixed. Bayer’s asundexian was stopped early in its AF trial for inferior efficacy versus apixaban, and milvexian’s LIBREXIA-ACS trial was stopped for futility in November 2025. Final ACS data at ESC Congress 2026 showed no efficacy benefit (5.4% vs. 5.1% event rate) but also no excess in serious bleeding, while lab measures confirmed the drug was anticoagulating as expected. That leaves LIBREXIA-STROKE (by year-end 2026) and LIBREXIA-AF as the real tests. In the short term the driver is binary. In the long term, if Factor XI works in stroke or AF, it could underpin a major new cardiovascular franchise in the 2030s, and BMY would be the company positioned to hand Eliquis patients over to a successor product.
Driver 3: Oncology is moving to next-generation IO and “IO 2.0” backbones. PD-1/PD-L1 inhibitors created a $50 billion-plus category (est.), but the next wave pairs PD-(L)1 blockade with VEGF inhibition in a single bispecific molecule. After strong trial data from Summit/Akeso’s ivonescimab, the industry piled into this approach. BMY’s entry is pumitamig (BNT327), a PD-L1 × VEGF-A bispecific co-developed with BioNTech, now in multiple global Phase 3 trials across lung, breast and gastric cancers. Interim Phase 2 data from ROSETTA Lung-02 in first-line non-small cell lung cancer showed high response rates across histologies and PD-L1 levels. Meanwhile, Opdivo Qvantig’s subcutaneous formulation is growing quickly ($261 million in Q2, more than triple the prior year) and could keep part of the Opdivo franchise on a newer, better-protected formulation. In the short term, IO revenue is flat to down (Opdivo IV was -3% in Q2). Over the long term, oncology remains the biggest growth pool in pharma, and BMY has several shots on goal.
Driver 4: Policy reshapes pricing but can expand volume. The IRA’s Medicare negotiation program set Eliquis’s maximum fair price at $231 per 30-day supply from January 1, 2026, down from a $521 list price. Many investors assumed this would shrink Eliquis revenue. The opposite happened: lower out-of-pocket costs and the redesign of Medicare Part D pushed U.S. Eliquis revenue up 27% in Q2 2026. The lesson is that for widely prescribed chronic drugs, lower patient cost sharing can drive volume that offsets net price cuts. The long-term flip side is that more BMY drugs will eventually be selected for negotiation, and “most-favored-nation” style pricing proposals remain an overhang for the whole sector.
2-3. Competitive Landscape
Large-cap pharma peer comparison (Finviz TTM data as of September 29, 2026)
Company Market Cap TTM Revenue Gross Margin Operating Margin Forward P/E Key Moat / Franchise Bristol Myers Squibb (BMY) $130.1B $49.2B 66.6% 32.4% 9.71x Eliquis, IO combinations, hematology/CELMoD, cell therapy Merck (MRK) $365.9B $66.3B 72.4% 18.8% 15.60x Keytruda, vaccines, animal health Pfizer (PFE) $164.2B $63.7B 64.8% 26.6% 9.95x Diversified primary care, vaccines, oncology (Seagen ADCs) AbbVie (ABBV) $472.5B $64.4B 71.4% 34.2% 16.27x Immunology (Skyrizi, Rinvoq), aesthetics, neuroscience Gilead (GILD) $186.5B $30.5B 79.7% 39.1% 15.15x HIV franchise, liver disease, oncology
Margins are GAAP-based TTM figures as compiled by Finviz; peer TTM earnings are distorted by one-time acquisition charges, so we compare on forward P/E rather than trailing P/E.
The table shows the market’s verdict clearly. BMY and Pfizer, both facing significant near-term LOE exposure, trade at about 10x forward earnings. AbbVie, which already absorbed its Humira cliff and proved that Skyrizi and Rinvoq could replace it, trades at over 16x. Merck, which faces its own Keytruda cliff in 2028, still carries a premium thanks to Keytruda’s subcutaneous conversion and broader franchise.
Why BMY is better positioned than the valuation implies:
– Profitability is competitive. BMY’s TTM operating margin of 32.4% is above Merck and Pfizer and close to AbbVie. The strategic productivity program cut non-GAAP SG&A by 11% in 2025, which gives it room to fund launches.
– Its growth drivers are diversified across modalities. A cardiac myosin inhibitor (Camzyos), an anemia biologic (Reblozyl), a CAR-T (Breyanzi), an oral CELMoD (iberdomide), a subcutaneous IO (Qvantig) and a muscarinic-targeting antipsychotic (Cobenfy) are not dependent on one scientific bet.
– Its catalysts are concentrated. Unlike peers whose value depends on slow share gains, BMY has multiple Phase 3 readouts within roughly 12 months. For a stock at 9.7x earnings, even partial success can drive a re-rating toward the peer average.
The honest counterpoint: AbbVie earned its premium by proving its replacement cycle, and BMY has not proven its yet. Cobenfy, the $14 billion Karuna acquisition, generated only $63 million in Q2 2026, and the key Alzheimer’s psychosis data has been pushed into 2027. Until the pipeline delivers, a discount to AbbVie is justified. A discount to Pfizer is harder to defend, given BMY’s higher margins and faster-growing Growth Portfolio.
—
3. Economic Moat Analysis
Moat Type 1: Intangible Assets (Patents, Regulatory Exclusivity and Know-How)
The core of any pharma moat is legal exclusivity: patents and FDA/EMA data exclusivity allow BMY to charge premium prices for 10–15 years of a product’s commercial life. The evidence of pricing power is clear in the margins. BMY’s non-GAAP gross margin was 71.4% in Q2 2026 and 72.6% for full-year 2025, and management guides to 69–70% for 2026 even with the mix shift toward lower-margin cell therapy and Eliquis volume.
In BMY’s case, the more durable intangible asset is scientific and manufacturing know-how in hard-to-copy modalities. Consider:
– Cell therapy (Breyanzi, Abecma): CAR-T therapies require individualized manufacturing, vein-to-vein logistics and treatment-center relationships. Even after patents expire, biosimilar-style competition in autologous cell therapy is essentially nonexistent. Breyanzi grew 82% in 2025 to $1.36 billion and another 41% in Q2 2026 to $484 million.
– Protein degradation (CELMoDs): BMY inherited Celgene’s decades of work on cereblon modulators (thalidomide, Revlimid, Pomalyst). Iberdomide’s August 2026 accelerated approval (described in FDA approval coverage as the first approved CELMoD agent) was based on a 41% rate of MRD-negative complete response vs. 21% for the comparator in the EXCALIBER-RRMM trial. Mezigdomide cut the risk of progression or death by 52% in SUCCESSOR-2 and has a May 2027 PDUFA date. This franchise lets BMY re-patent its myeloma leadership as Revlimid and Pomalyst generics arrive.
– Formulation and lifecycle management: Opdivo Qvantig, the subcutaneous version of Opdivo, has its own patent estate. Every patient moved from IV to subcutaneous before the 2028 IV LOE is partly insulated from biosimilars.
Moat Type 2: Switching Costs and Clinical Entrenchment
Physicians do not switch therapies lightly for stable patients, especially in cardiology and oncology, where changing drugs carries clinical risk. Eliquis is the clearest example. It is embedded in AF treatment guidelines, hospital protocols and years of physician habit, and it keeps gaining volume even at a negotiated Medicare price. U.S. Eliquis revenue grew 27% in Q2 2026. Camzyos has a similar dynamic: it requires echocardiogram monitoring and REMS enrollment, which creates an up-front burden for prescribers. Once a cardiology practice has built that workflow, it has an incentive to keep using the drug. Camzyos revenue grew 77% in 2025 to $1.07 billion and 60% in Q2 2026. The switching-cost moat also shows up in Reblozyl, which has become widely used for anemia in lower-risk myelodysplastic syndromes, and in Orencia’s steady +7% growth in rheumatoid arthritis despite a crowded market.
There is also a scale component. BMY spends about $16.5 billion a year on SG&A and R&D combined (2026 guidance). That funding level lets it run large global Phase 3 programs such as LIBREXIA, which enrolls over 50,000 patients across three studies with J&J, and maintain a global commercial footprint. Small biotechs cannot replicate this, which is why they partner with or sell to BMY.
Moat Durability Assessment
Will BMY’s moat hold over 5–10 years? Partially, and the answer depends on product-level turnover, not on the company. The biggest weakness is that pharma moats expire by design. The Eliquis switching-cost moat ends in April 2028, when generic apixaban can launch in the U.S.; clinical loyalty does not survive a 70–90% price drop in a primary-care drug. Opdivo IV faces biosimilars around the same time. Consensus data compiled by TIKR shows the Street expecting BMY revenue to fall to about $36.2 billion by 2030, a decline of roughly 5.5% a year from 2025 (about 25% cumulatively).
Specific risks to the moat:
1. Faster-than-expected erosion. Generic erosion is often faster than models assume, as Revlimid (-49% in 2025) and Pomalyst (-71% in Q2 2026) showed.
2. Policy erosion. IRA negotiation and possible most-favored-nation pricing could cut the effective exclusivity period for small-molecule drugs.
3. Competitive leapfrogging. PD-1 × VEGF bispecifics could make Opdivo-based regimens obsolete if BMY’s pumitamig program underdelivers.
The counterarguments are real, though. BMY’s newer franchises (cell therapy, CELMoDs, Camzyos, Reblozyl) have patent protection well into the 2030s. The company has a proven lifecycle playbook, and its productivity program has lowered the revenue base it needs to sustain margins. Our assessment: the company-level moat is narrow but sustainable, and the product-level moats are refreshing faster than the market assumes. The next 12 months of Bristol Myers Squibb pipeline readouts will show how fast.
—
4. Financial Analysis
Five-year income statement summary ($ millions, except per-share data)
Metric 2022 2023 2024 2025 TTM (to Q2 2026) 2026 Guidance Revenue 46,159 45,006 48,300 48,194 ~49,200 ~49,000–50,000 YoY Growth -0.5% -2.5% +7.3% -0.2% — ~+2–4% Net Income (GAAP) 6,327 8,025 (8,948) 7,054 ~9,280 — Diluted EPS (GAAP) 2.95 3.86 (4.41) 3.46 4.54 — EPS (non-GAAP) 7.70 7.51 1.15 6.15 — 6.75–7.00 Growth Portfolio Revenue — — 22,563 26,409 — —
Sources: BMS annual reports and earnings releases (8-K); TTM figures from Finviz. 2024 GAAP and non-GAAP results include roughly $13.4 billion of acquired IPRD charges, mainly from the Karuna acquisition.
The story behind each year:
– 2022–2023 (revenue decline, -0.5% and -2.5%): Revlimid generics started volume-limited U.S. entry in 2022, and the Legacy decline outpaced new launches. Non-GAAP EPS stayed above $7.50 because the high-margin Celgene products were still largely intact.
– 2024 (+7.3% revenue, GAAP loss): Revenue rebounded on Eliquis, Opdivo, Breyanzi and Reblozyl, but the Karuna, RayzeBio and Mirati acquisitions generated about $13.4 billion of acquired IPRD charges. That drove a GAAP net loss of $8.9 billion and non-GAAP EPS of only $1.15. Treat 2024 as a one-time accounting trough, not an operating trough.
– 2025 (flat revenue, EPS recovery): Revenue of $48.19 billion was flat as the Growth Portfolio (+17%, to $26.4 billion) offset a steep Legacy decline (Revlimid -49%). Non-GAAP EPS recovered to $6.15, including a $1.40 drag from acquired IPRD and licensing. The productivity program cut non-GAAP SG&A by 11%.
– 2026 (guidance raised): First-half revenue rose 4.2% to $24.46 billion. Q2 alone rose 6% with non-GAAP EPS up 40% to $2.04, well above the roughly $1.60 consensus. Full-year non-GAAP EPS guidance rose from $6.05–6.35 to $6.75–7.00.
Key operating metrics:
Metric Value Comment Growth Portfolio growth (Q2 2026) +15% (+14% ex-FX) Accelerated from +12% in Q1 Growth Portfolio share of revenue (Q2 2026) 58.3% Up from 54.8% for full-year 2025 Legacy Portfolio (Q2 2026) $5.42B, -4% Eliquis growth offset generics Non-GAAP gross margin (Q2 2026) 71.4% -120 bps YoY on mix Non-GAAP R&D (Q2 2026) $2.32B, +2% Disciplined despite a heavy late-stage pipeline Non-GAAP effective tax rate (Q2 2026) 16.5% FY guide ~18%
Profitability and returns (Finviz TTM): gross margin 66.6%, operating margin 32.4%, net margin 18.9%, ROE 46.7% and ROA 10.2%. The high ROE is partly a product of leverage (Debt/Equity 2.02) and a book value reduced by acquisition-related write-offs, so it overstates underlying capital efficiency. Still, a 32% operating margin on $49 billion of revenue is a strong cash engine.
Balance sheet and cash flow:
Item June 30, 2026 Dec 31, 2025 Cash, equivalents & marketable securities $11.46B $11.07B Short-term debt $1.03B $2.26B Long-term debt $42.09B $42.85B Net debt $31.66B $34.04B
Net debt fell by $2.4 billion in the first half of 2026 and is down from $38.47 billion at the end of 2024, a $6.8 billion reduction in 18 months. BMY generated roughly $12.8 billion of free cash flow in 2025 (as compiled by TIKR). With 2.04 billion shares and a $2.52 annual dividend, the dividend costs about $5.1 billion a year, or roughly 40% of 2025 FCF. That leaves about $7–8 billion a year for debt reduction and business development. Interest expense was $1.89 billion in 2025, which is manageable relative to pre-tax earnings.
Margin story: BMY’s margin question is about defense, not expansion. Gross margin is drifting down (72.6% in 2025 to a 69–70% guide in 2026) as the mix shifts toward Eliquis volume at the negotiated price and toward cell therapy. Operating expenses are guided up to about $16.5 billion to fund launches and pipeline programs. The offset is revenue scale: every $1 billion of extra Growth Portfolio revenue at roughly 70% gross margin adds about $0.25–0.30 of EPS after tax (est.). Management’s guidance raise, about $2.75 billion of revenue at the midpoint turning into about $0.68 of extra EPS at the midpoint (after higher opex), is consistent with that math.
—
5. Valuation: Pricing the Cliff, Paying Little for the Pipeline
Method choice: BMY is solidly profitable, so a P/E approach is appropriate. We anchor on consensus forward EPS (EPS next Y) of $6.56, as reported by Finviz, and cross-check with EV/Sales, dividend yield and FCF yield. We deliberately use the forward figure rather than 2026 guidance ($6.75–7.00), because the Street already models 2027 EPS about 5% below the 2026 guidance midpoint to reflect Legacy erosion and higher investment.
Current multiples (price $63.70):
– Trailing P/E: $63.70 ÷ $4.54 = 14.03x (GAAP TTM EPS)
– Forward P/E: $63.70 ÷ $6.56 = 9.71x
– P/S: 2.65x; P/B: 5.83x
– Enterprise value: $130.12B market cap + $31.66B net debt ≈ $161.8B, or about 3.3x TTM sales
– Dividend yield: $2.52 ÷ $63.70 ≈ 4.0%
– FCF yield (2025 FCF): $12.8B ÷ $130.1B ≈ 9.8%
Step 1 — Choose a multiple range. The large-cap pharma peers in Section 2 trade at 9.95x (Pfizer) to 16.27x (AbbVie) forward earnings. BMY’s own history is instructive: for much of 2023–2024 the stock traded at high-single-digit forward multiples (approx.) while investors feared the cliff, and it re-rated as the Growth Portfolio proved itself.
– Bear multiple: 8.0x. Assumes LIBREXIA-STROKE fails, ADEPT disappoints, and the market reverts to pricing BMY as a pure run-off story.
– Base multiple: 10.5x. Modest re-rating to Pfizer-plus, reflecting better margins, a +15% Growth Portfolio and mixed pipeline outcomes.
– Bull multiple: 12.5x. At least one major readout succeeds (milvexian in stroke or AF, or admilparant in IPF), giving the market visibility on post-2028 replacement revenue. This is still well below AbbVie’s 16x.
Step 2 — Apply to forward EPS of $6.56.
Scenario Forward P/E EPS Price Target vs. $63.70 Probability Bear 8.0x $6.56 $52.48 → $52 -17.6% 20% Base 10.5x $6.56 $68.88 → $69 +8.1% 50% Bull 12.5x $6.56 $82.00 → $82 +28.7% 30%
Step 3 — Probability-weighted target:
0.20 × $52.48 + 0.50 × $68.88 + 0.30 × $82.00 = $10.50 + $34.44 + $24.60 = $69.54 → $70 target, about 9.9% upside. Add the roughly 4.0% dividend yield and the expected 12-month total return is about 14%.
Cross-checks:
– Dividend yield: At our $70 target, the yield on the current $2.52 dividend would be 3.6%. That is in line with where high-quality pharma dividend payers trade when growth is stable. At the bear case of $52, the yield would be 4.8%, which should attract income buyers and helps limit the downside.
– FCF yield: Even if FCF falls 20% after 2028 (to about $10 billion), the current market cap implies a 7.7% FCF yield. That is not the valuation of a business the market expects to grow.
– EV/Sales: At 3.3x TTM sales, BMY trades well below where branded pharma typically trades when the pipeline has credibility.
Comparison with analyst consensus: The Finviz consensus target is $66.57, about 4.5% upside, and the rating mix is heavily “Hold.” Piper Sandler raised its target to $82 (Overweight) on September 16, 2026, citing upcoming pivotal milestones for milvexian, Cobenfy and admilparant. Guggenheim moved to $75 (Buy) after Q2. Our $70 target is modestly above consensus. We agree with the Street that the 2028 cliff is real, and we disagree on how much the market pays for the pipeline. At 9.7x forward earnings, the stock prices close to zero probability of success for the late-stage readouts. We think a 30% chance of at least one major win is conservative given the breadth of the program. The asymmetry is where the value lies: in the bear case the stock is cushioned by a roughly 4.8% yield and a 7%+ FCF yield, and in the bull case it re-rates toward peers.
—
6. Risk Factors
Risk 1: The 2028 double patent cliff (Eliquis and Opdivo). This is the dominant risk. Eliquis ($14.44 billion in 2025) and Opdivo ($10.05 billion in 2025) together made up about 51% of 2025 revenue. Generic apixaban can enter the U.S. on April 1, 2028, and Opdivo IV faces biosimilar competition around the same time. Primary-care small molecules like Eliquis typically lose most of their U.S. revenue within 12–24 months of multi-source generic entry. The Revlimid experience inside BMY’s own portfolio (revenue down from about $5.8 billion in 2024 to $2.95 billion in 2025) shows how fast this can happen. The Street’s roughly $36 billion 2030 revenue estimate assumes much of this erosion. The risk is that erosion is faster or deeper than modeled, or that Opdivo Qvantig conversion stalls, leaving a larger gap for the Growth Portfolio to fill. If the Growth Portfolio cannot grow at double digits through 2030, earnings could fall faster than the consensus $6.56 forward estimate implies, and even a low multiple would not protect the stock.
Risk 2: Pipeline binary outcomes and a pattern of delays. Much of our bull case depends on late-stage readouts, and the recent track record is mixed. Milvexian already failed in ACS (5.4% vs. 5.1% event rate, stopped for futility), and Bayer’s asundexian, a Factor XIa inhibitor from the same class, failed in AF. The LIBREXIA-AF readout has been pushed beyond the original 2026 timeline. Cobenfy’s ADEPT program in Alzheimer’s disease psychosis has been delayed more than once, first because of trial-site “irregularities” and then because of slow enrollment in ADEPT-2 and ADEPT-4 and slow relapse accrual in ADEPT-1. Topline data is now expected to start in early 2027. Meanwhile, Cobenfy’s commercial ramp in schizophrenia has been slow, with $63 million of Q2 revenue against an acquisition price of about $14 billion. If LIBREXIA-STROKE and admilparant both fail around year-end 2026, the market will likely assign even less value to the remaining pipeline, and the stock could revisit the bear-case zone near $52.
Risk 3: U.S. drug pricing policy. About 69% of BMY’s revenue is from the U.S., more than many peers. The IRA negotiation program has already reset Eliquis’s Medicare price, and more BMY products could be selected in future rounds. Small-molecule drugs such as Camzyos, Cobenfy and future oral CELMoDs are especially exposed, because under the IRA, negotiated prices for small molecules can take effect about nine years after approval versus about 13 years for biologics. Proposals to link U.S. prices to lower international prices (“most-favored-nation” pricing) remain a sector-wide overhang. Eliquis’s 2026 volume surge shows that lower patient costs can raise revenue in some cases, but that pattern is unlikely to hold for specialty drugs with narrower patient populations. A broader policy shift could compress the pricing power behind BMY’s 70%-range gross margin.
Risk 4 (secondary): Capital allocation and leverage. Net debt of $31.7 billion (Debt/Equity 2.02) is falling but still material. BMY’s history includes expensive acquisitions (Celgene, Karuna) whose returns are still being proven. A large, dilutive deal done under pressure to fill the 2028 gap could hurt returns and slow the pace of deleveraging.
—
7. Conclusion & Exit Plan
Rating: Buy (income-plus-catalyst position)
Bristol Myers Squibb is an unusual large-cap setup where the fundamentals are improving, guidance was just raised by about $2.75 billion of revenue, the Growth Portfolio is growing 15%, and net debt is falling, while the stock still trades at 9.7x forward earnings with a 4.0% dividend yield. The market is right that 2028 will be painful. We think it is wrong to assign almost no value to a late-stage pipeline with multiple readouts over the next 12 months. The upcoming Bristol Myers Squibb pipeline readouts are the key: a single major win should push the multiple toward 12x or more, while a string of failures is partly cushioned by the dividend and the cash flow.
Entry price range: $58–64. At $64 or below, the starting yield at the current dividend rate is about 3.9% or more, and investors pay about 9.8x or less forward EPS. We would add more aggressively on any pullback toward $58 (about 8.8x forward EPS, a 4.3% yield) ahead of the year-end readouts. Above $68, most of our base case is priced in and risk/reward becomes balanced.
Exit conditions:
– Target achieved: Trim one-third at our $70 probability-weighted target. Sell the remainder near the bull-case $82 unless a positive readout has raised forward EPS estimates.
– Fundamental break: Sell if (a) both LIBREXIA-STROKE and admilparant’s IPF Phase 3 fail to meet primary endpoints, and Growth Portfolio growth drops below 8% for two consecutive quarters; or (b) management cuts the dividend or signals a large debt-funded acquisition that pushes net debt back above $40 billion.
– Time-based: Reassess after LIBREXIA-STROKE topline results (expected by year-end 2026) and again after the first ADEPT readouts in 2027. If the stock has not reached $66 by Q2 2027 and there is no positive readout, revisit the thesis.
Catalyst calendar to watch:
Timing Catalyst Late 2026 LIBREXIA-STROKE (milvexian) topline; admilparant IPF Phase 3; possible ADEPT-1 interim Early 2027 Admilparant progressive pulmonary fibrosis readout; ADEPT readouts begin Mar 11, 2027 Reblozyl PDUFA (myelofibrosis-associated anemia) May 13, 2027 Mezigdomide PDUFA (relapsed/refractory multiple myeloma) Apr 1, 2028 Earliest U.S. generic Eliquis entry
Summary table:
Item Detail Company Bristol Myers Squibb (BMY) Current Price $63.70 Target Price $70 (probability-weighted; base $69 / bull $82 / bear $52) Upside 9.9% (about 14% total return including a 4.0% dividend yield) Rating Buy Key Thesis 9.7x forward P/E prices in the 2028 cliff but assigns almost no value to a dense late-stage pipeline, while the Growth Portfolio compounds at 15% Main Risk Eliquis and Opdivo LOE in 2028 (about 51% of 2025 revenue) combined with failed or delayed Phase 3 readouts
—
Disclaimer
This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-09-29) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.
함께 읽으면 좋은 글
- CrowdStrike Falcon Flex Net New ARR Analysis: A $333M Quarter, 155x Forward Earnings, and Why Our Base Case Is $232
- FedEx Post-Spin-Off Network 2.0 Margin Expansion: Why Pure-Play Parcel FedEx Is Worth $323 (13% Upside)
- Quanta Services Grid Labor Bottleneck After the Bernstein Upgrade: $53.4B Backlog and a $742 Base-Case Target
- Costco Q4 FY2026 Earnings and Membership Renewal Analysis: 92.3% Retention, 9.4% Comps, and a $1,045 Fair Value
- Cintas UniFirst Acquisition Impact on Stock: Record 23.6% Margin and a $209 Base-Case Target
참고 자료
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 (SEC 8-K)
- Bristol Myers Squibb Reports Fourth Quarter and Full-Year 2025 Results (SEC 8-K)
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays – BioSpace
- Milvexian did not reduce cardiovascular events in the LIBREXIA ACS trial – ESC
- FDA grants accelerated approval to iberdomide for multiple myeloma – FDA
- BMY Reiterated by Piper Sandler — Price Target Raised to $82.00 – GuruFocus
- Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof – TIKR
- Global Medicine Spending to Reach $2.3 Trillion by 2028 – IQVIA